Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pomalidomide versus placebo in transfusion-dependent myelofibrosis anemia
NL-OMON39241Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Oct 2011
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pomalidomide in myelofibrosis (MF), sponsored by Celgene Corporation. Started Oct 2011; status: active, not recruiting.
02
Drugs
pomalidomide
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON39241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39241.